4-Hydroxy-2-methylpyrido<2,3-d>pyridazin-1-on | 54016-02-3

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪类
• 英文名称: 4-Hydroxy-2-methylpyrido<2,3-d>pyridazin-1-on
• 英文别名: 6-methyl-7H-pyrido[2,3-d]pyridazine-5,8-dione
• CAS: 54016-02-3
• 化学式: C₈H₇N₃O₂
• 分子量: 177.162
• InChiKey: GYQOMGQKAPSSKZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  -0.1
• 重原子数：
  13
• 可旋转键数：
  0
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.12
• 拓扑面积：
  62.3
• 氢给体数：
  1
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  4-Hydroxy-2-methylpyrido<2,3-d>pyridazin-1-on 在 三氯氧磷 作用下， 以0.11 g的产率得到8-chloro-6-methylpyrido[2,3-d]pyridazin-5(6H)-one
  参考文献：
  名称：

  PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

  摘要：

  Provided herein are heterocyclic phenyl compounds useful as degraders of KAT2, as well as compositions and methods of use thereof.

  公开号：

  WO2024050078A1
• 作为产物：
  描述：

  甲基肼 、 2,3-吡啶二甲酸二甲酯 以 水 为溶剂， 生成 4-Hydroxy-2-methylpyrido<2,3-d>pyridazin-1-on
  参考文献：
  名称：

  PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS

  摘要：

  Provided herein are heterocyclic phenyl compounds useful as degraders of KAT2, as well as compositions and methods of use thereof.

  公开号：

  WO2024050078A1

文献信息

• [EN] PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER<br/>[FR] DÉRIVÉS PHTALAZINE DE FORMULE (I) UTILISÉS COMME INHIBITEURS DE LA PCAF ET DE LA GCN5 DESTINÉS À ÊTRE UTILISÉS DANS LE TRAITEMENT DU CANCER
  申请人：GENENTECH INC

  公开号：WO2016036954A1

  公开（公告）日：2016-03-10

  The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

  本发明涉及使用式(I)的化合物或其药学上可接受的盐治疗由PCAF和GCN5介导的疾病的方法：其中环A、R1、R3、R4、R5和每个Re具有规范中定义的任何值。还包括式(I)的新化合物及其盐，以及包含式(I)的化合物或其药学上可接受的盐的药物组合物。
• Therapeutic compounds and uses thereof
  申请人：GENENTECH, INC.

  公开号：US10155764B2

  公开（公告）日：2018-12-18

  The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R1, R3, R4, R5, and each Re have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.

  本发明涉及使用式（I）化合物或其药学上可接受的盐治疗 PCAF 和 GCN5 介导的疾病的方法： 其中环 A、R1、R3、R4、R5 和各 Re 具有说明书中定义的任一值。还包括新型的式 (I) 化合物及其盐，以及包含式 (I) 化合物或其药学上可接受的盐的药物组合物。
• PHTHALAZINE DERIVATIVES OF FORMULA (I) AS PCAF AND GCN5 INHIBITORS FOR USE IN THE TREATMENT OF CANCER
  申请人：Genentech, Inc.

  公开号：EP3189049A1

  公开（公告）日：2017-07-12
• THERAPEUTIC COMPOUNDS AND USES THEREOF
  申请人：GENENTECH, INC.

  公开号：US20170275289A1

  公开（公告）日：2017-09-28

  The present invention relates to methods for treating PCAF and GCN5 mediated disorders using a compound of formula (I) or a pharmaceutically acceptable salt thereof: wherein ring A, R 1 , R 3 , R 4 , R 5 , and each R e have any of the values defined in the specification. Also included are novel compounds of Formula (I) and salts thereof, as well as pharmaceutical compositions comprising a compound of formula (I) or a pharmaceutically acceptable salt thereof.
• PYRIDAZINON DERIVATIVES AS KAT2 DEGRADERS FOR THE TREATMENT OF PROLIFERATIVE DISORDERS
  申请人：[en]AURON THERAPEUTICS, INC.

  公开号：WO2024050078A1

  公开（公告）日：2024-03-07

  Provided herein are heterocyclic phenyl compounds useful as degraders of KAT2, as well as compositions and methods of use thereof.